

## Euglycemic Diabetic Ketoacidosis – A Rare Adverse Effect of Sodium-Glucose Co-Transporter-2 Inhibitors Therapy in type 2 Diabetes: A Case Report

**Dr. Pranshu Chawla**

Dashmesh Hospital, Janakpuri, New Delhi, India

**Dr. Purvi Sukhwai**

Dashmesh Hospital, Janakpuri, New Delhi, India

### Abstract:

Euglycemic diabetic ketoacidosis (EuDKA) is an uncommon but increasingly recognised complication of diabetes, particularly associated with the growing use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors. Unlike classic diabetic ketoacidosis (DKA), EuDKA presents with normal or only mildly elevated blood glucose levels, making timely diagnosis challenging. We report the case of a 70-year-old woman with type 2 diabetes mellitus who was hospitalized for percutaneous transluminal coronary angioplasty (PTCA) and developed dapagliflozin-associated euglycemic diabetic ketoacidosis in the postoperative period, despite discontinuation of the drug prior to the procedure. This case underscores the importance of maintaining a high index of suspicion for EuDKA in patients previously on SGLT-2 inhibitors, especially in the perioperative setting. Early recognition and prompt management are crucial to prevent serious complications and improve clinical outcomes.

### Keywords:

Euglycemic Ketoacidosis, SGLT-2 inhibitor, Dapagliflozin, High anion gap metabolic acidosis.